The Mount Sinai Conference on the pharmacotherapy of schizophrenia

Schizophrenia Bulletin

Volumn 28, Issue 1, 2002, Pages 5-16

  Marder, Stephen R ^a   Essock, Susan M ^a   Miller, Alexander L ^a   Buchanan, Robert W ^a   Davis, John M ^a   Kane, John M ^a   Lieberman, Jeffrey ^a   Schooler, Nina R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Clozapine; Evidence based practice; Schizophrenia; Tardive dyskinesia

Indexed keywords

CLOZAPINE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MENTAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA; CLASSIFICATION; CLINICAL PATHWAY; COMPARATIVE STUDY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DYSKINESIA; PSYCHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CRITICAL PATHWAYS; DYSKINESIA, DRUG-INDUCED; EVIDENCE-BASED MEDICINE; HUMANS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0035988520     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006926     Document Type: Article

References (44)

1. Sexual dysfunction in male schizophrenic patients
2. Antipsychotic-induced weight gain: A comprehensive research synthesis
3. Practice guidelines for the treatment of patients with schizophrenia
4. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
5. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
6. Positive and negative symptom response to clozapine in deficit and nondeficit patients
7. Clozapine: Its impact on aggressive behavior among patients in a state psychiatric hospital
8. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
9. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia
10. A randomized doubleblind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
11. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response
12. Maintenance antipsychotic medication
13. Risperidone in the treatment of first episode psychotic patients: A double-blind multicenter study
14. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals
15. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
16. Paranoid and withdrawal symptoms in schizophrenia: Differential symptom reduction over time
17. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
18. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
19. Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride
20. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders
21. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
22. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia
23. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
24. Clozapine and haloperidol in moderately refractory schizophrenia: A six month double-blind comparison
25. Does clozapine cause tardive dyskinesia?
26. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
27. At Issue: Translating research into practice: The schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations
28. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
29. Time course and biologic correlates of treatment response in first-episode schizophrenia
30. Effect of clozapine on the reduction of suicidality in schizophrenia and schizoaffective disorder
31. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
32. The Texas Medication Algorithm Project (TMAP) schizophrenia algorthms
33. Olanzapine increases weight and serum triglyceride levels
34. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder
35. Reproductive and sexual adverse effects of psychotropic durgs
36. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
37. Olanzapine versus haloperidol treatment in first-episode psychosis
38. Impact of clozapine on completed suicide
39. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
40. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
41. Mortality in current and former users of clozapine
42. Risperidone in treatment-refractory schizophrenia